{"gene":"BCAT1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2013,"finding":"BCAT1 initiates catabolism of branched-chain amino acids (BCAAs) in glioblastoma; suppression of BCAT1 in glioma cell lines blocked glutamate excretion and reduced proliferation and invasiveness in vitro, and decreased tumor growth in xenograft models. BCAT1 expression was dependent on α-ketoglutarate substrate concentration and could be suppressed by ectopic overexpression of mutant IDH1 in immortalized human astrocytes, linking IDH1 function to BCAT1 expression.","method":"shRNA knockdown in glioma cell lines, xenograft mouse model, ectopic mutant IDH1 overexpression in astrocytes, glutamate excretion assay","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, epistasis with IDH1, replicated across cell lines and xenograft model","pmids":["23793099"],"is_preprint":false},{"year":2017,"finding":"BCAT1 is a critical regulator of intracellular α-ketoglutarate (αKG) homeostasis in AML stem cells: it transfers α-amino groups from BCAAs to αKG, consuming αKG. Knockdown of BCAT1 caused αKG accumulation, leading to EGLN1-mediated HIF1α protein degradation and growth/survival defects. Overexpression of BCAT1 decreased intracellular αKG and caused DNA hypermethylation through reduced TET enzyme activity, mimicking IDH mutation effects.","method":"BCAT1 knockdown and overexpression in leukemia cells, high-resolution proteomics, intracellular metabolite measurements (αKG), HIF1α protein level analysis, TET activity assay, DNA methylation profiling","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods (metabolomics, protein degradation assays, epigenomic profiling), gain-of-function and loss-of-function in same study","pmids":["29144447"],"is_preprint":false},{"year":2017,"finding":"BCAT1 promotes mitochondrial biogenesis, ATP production, and represses mitochondrial ROS in breast cancer cells by activating mTOR (but not AMPK or SIRT1) signaling. Knockdown of BCAT1 repressed cell growth and colony formation.","method":"BCAT1 knockdown and overexpression in breast cancer cells, mTOR/AMPK/SIRT1 pathway Western blot, mitochondrial biogenesis and ATP assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single lab, multiple orthogonal functional assays but no in vivo confirmation","pmids":["28235484"],"is_preprint":false},{"year":2014,"finding":"TCR activation of CD4+ T cells triggers expression of cytosolic BCATc (BCAT1), which increases leucine transamination and lowers intracellular leucine. BCATc(-/-) T cells have higher intracellular leucine, elevated mTORC1 activation (increased phospho-S6 and 4EBP-1), and higher glycolytic rates than wild-type T cells. BCATc induction by TCR is blocked by the calcineurin/NFAT inhibitor cyclosporin A, placing NFAT upstream of BCAT1 expression.","method":"BCATc knockout mouse (BCATc-/-), leucine transamination assays, mTORC1 phosphorylation (S6, 4EBP-1) by Western blot, glycolysis measurements, cyclosporin A pharmacological inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO mouse model with biochemical pathway validation, multiple orthogonal readouts","pmids":["24847056"],"is_preprint":false},{"year":2013,"finding":"c-Myc directly binds to the c-Myc binding site in the BCAT1 promoter and upregulates BCAT1 expression in nasopharyngeal carcinoma (NPC). Knockdown of c-Myc downregulates BCAT1, and BCAT1 knockdown reduces NPC cell proliferation, migration, and invasion.","method":"ChIP assay (c-Myc binding to BCAT1 promoter), luciferase reporter assay, c-Myc siRNA knockdown, BCAT1 siRNA knockdown, colony formation, migration and invasion assays","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct ChIP and luciferase reporter validation of c-Myc→BCAT1 promoter binding, supported by siRNA functional assays","pmids":["23758864"],"is_preprint":false},{"year":2020,"finding":"In pancreatic cancer stroma, TGF-β–SMAD5 axis directly targets BCAT1 in cancer-associated fibroblasts (CAFs), dictating internalization of extracellular matrix to supply amino-acid precursors for BCKA secretion, which is then utilized by adjacent cancer cells.","method":"TGF-β–SMAD5 pathway perturbation in CAFs, BCAT1 expression measurement, metabolic flux analysis (isotope tracing), circulating tumor cells and PDAC tissue slice validation","journal":"Nature metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis with TGF-β/SMAD5 and metabolic tracing, single lab but multiple methods including patient-derived material","pmids":["32694827"],"is_preprint":false},{"year":2004,"finding":"BCATc (BCAT1) is expressed exclusively in neurons in the adult rat brain. In glutamatergic neurons (e.g., granule cells of cerebellum and dentate gyrus), BCATc localizes to axons and nerve terminals; in GABAergic neurons (Purkinje cells, hippocampal pyramidal basket cells), it is concentrated in cell bodies. BCATc is strongly expressed in the mossy fiber pathway. This localization supports a role in modulating glutamate availability for neurotransmitter release or GABA synthesis.","method":"Immunohistochemistry in rat brain sections, cell-type specific localization in neuronal subtypes","journal":"The Journal of comparative neurology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct immunohistochemical localization across multiple brain regions and cell types, single lab","pmids":["15329886"],"is_preprint":false},{"year":2022,"finding":"BCAT1 localizes to mitotic structures and has a non-metabolic function as a mitotic regulator. The BCAT1 CXXC redox motif controls cysteine sulfenylation specifically in mitotic cells, promotes Aurora kinase B localization to centromeres, and is required for accurate chromosome segregation in cancer and iPSC cells. Loss of BCAT1 causes mitotic errors; rescue requires the intact CXXC motif, not catalytic BCAA transaminase activity.","method":"Gene knockout and rescue with CXXC mutant vs. wild-type BCAT1, live-cell imaging of mitotic structures, immunofluorescence of Aurora B at centromeres, cysteine sulfenylation assay, human cerebral organoid and mouse syngraft tumor models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic rescue with separation-of-function mutant (CXXC), multiple orthogonal methods, in vitro and in vivo validation","pmids":["36260995"],"is_preprint":false},{"year":2022,"finding":"The BCAT1 CXXC motif can metabolize H2O2 in vitro (novel antioxidant activity), whereas CXXC-mutant BCAT1 or wild-type BCAT2 cannot. In AML cells, overexpression of wild-type BCAT1 reduces intracellular ROS compared to CXXS mutant, reduces myeloid differentiation markers, and protects against apoptosis, implicating the BCAT1 CXXC motif in redox buffering and myeloid differentiation block.","method":"In vitro H2O2 metabolism assay with purified BCAT1 protein (WT vs. CXXC mutant), intracellular ROS measurement in U937 AML cells, flow cytometry for myeloid markers and apoptosis","journal":"Antioxidants (Basel, Switzerland)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with purified protein and mutagenesis, cell-based validation with WT vs. mutant rescue","pmids":["35453368"],"is_preprint":false},{"year":2023,"finding":"BCAT1 directly interacts with RhoC (identified by co-IP/pulldown), leading to elevation of RhoC GTPase activity. Additionally, the BCAA-derived metabolite branched-chain α-keto acid (BCKA) directly binds to RhoC and promotes its activity. A gain-of-function BCAT1 E61A mutation (enriched in gastric cancer) confers higher enzymatic activity, boosting BCAA catabolism, cell motility, and tumor development. BCAT1 KO-suppressed cell motility is rescued by BCAT1E61A expression or BCKA supplementation.","method":"Co-immunoprecipitation (BCAT1–RhoC interaction), RhoC GTPase activity assay, BCKA-RhoC direct binding assay, BCAT1 E61A mutant expression, BCAT1 knockout rescue experiments, in vitro motility assays, in vivo peritoneal metastasis model","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding assays (Co-IP, BCKA–RhoC), functional mutant rescue, multiple orthogonal readouts in single lab","pmids":["37337119"],"is_preprint":false},{"year":2022,"finding":"Loss of BCAT1 in IDH-wildtype GBM cells increases NAD+/NADH ratio but impairs oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis. Supplementing αKG in BCAT1-loss cells causes synthetic lethality (not seen with loss of BCAT2, BCKDHA, or GPT2). Synthetic lethality is prevented by supplementation with BCKA (downstream BCAT1 products), placing BCAT1 in the pathway supplying BCKA for mitochondrial metabolism and biosynthesis.","method":"Metabolic synthetic lethal screen, BCAT1 KO in patient-derived GBM cells, BCKA supplementation rescue, NAD+/NADH ratio measurement, mTORC1 activity assay, nucleotide quantification, in vivo xenograft model with gabapentin + αKG cotreatment","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — comprehensive metabolic profiling with genetic and pharmacological perturbations, in vitro and in vivo validation, metabolite rescue experiments","pmids":["35499760"],"is_preprint":false},{"year":2021,"finding":"BCAT1 enzymatic activity is required for osteoclast maturation: selective inhibition with gabapentin or expression of enzymatically dead BCAT1 (active-site mutant) abrogated RANKL-induced osteoclast differentiation. Valine was the most critical BCAA for osteoclast maturation, and BCAT1 activity sustains BCAA catabolism needed for this process.","method":"Gabapentin pharmacological inhibition, enzymatically dead BCAT1 mutant expression, RANKL-induced osteoclast differentiation assay, BCAA supplementation/depletion, in vivo LPS-induced calvarial bone loss model","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic-dead mutant and pharmacological inhibitor with in vivo model, single lab","pmids":["35760874"],"is_preprint":false},{"year":2020,"finding":"BCAT1 binds the RNA-binding protein ZNF423 via AU-rich elements in the BCAT1 mRNA 3'-UTR (posttranscriptional regulation). BCAT1 protein then binds IRE1 on the ER to activate the IRE1–XBP-1–RIDD axis, leading to upregulation of BECN1 and Atg5 and autophagy activation in hypoxic pulmonary artery smooth muscle cells.","method":"RNA binding protein pulldown (ZNF423–BCAT1 mRNA), Co-IP (BCAT1–IRE1), BECN1/Atg5 protein expression assays, autophagy flux analysis in hypoxic PASMCs and rat model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and RNA pulldown for binding interactions, pathway activation measured with downstream markers, single lab","pmids":["32938905"],"is_preprint":false},{"year":2024,"finding":"BCKDK (branched chain ketoacid dehydrogenase kinase) phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability. STUB1 (CHIP) is the E3 ubiquitin ligase for BCAT1, ubiquitinating it for proteasomal degradation. BCKDK also phosphorylates STUB1 at S19, which disrupts the STUB1–BCAT1 interaction and inhibits BCAT1 ubiquitin-mediated degradation. This BCKDK–STUB1–BCAT1 cross-talk promotes GBM proliferation and temozolomide resistance.","method":"Phosphorylation site mapping (S5/S9/T312), BCKDK kinase assay, Co-IP (STUB1–BCAT1 interaction), ubiquitination assay (K48-linkage), STUB1 site mutants, in vivo and in vitro proliferation assays, temozolomide sensitivity assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-specific phosphorylation and ubiquitination with mutagenesis, Co-IP interaction studies, single lab","pmids":["38621458"],"is_preprint":false},{"year":2024,"finding":"CHIP (STUB1) acts as an E3 ubiquitin ligase for BCAT1, interacting via its coiled-coil domain with BCAT1 to promote K48-linkage ubiquitin degradation via the proteasome at Lys360. CHIP-mediated BCAT1 degradation induces metabolic reprogramming, reduces glutathione (GSH) synthesis, increases oxidative stress, and sensitizes glioma cells to temozolomide.","method":"Co-IP (CHIP–BCAT1), ubiquitination site mapping (Lys360), domain mapping (CHIP coiled-coil), proteasome inhibitor rescue, in vitro and in vivo tumor growth, GSH quantification","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct E3–substrate interaction with site mapping and functional consequences, single lab","pmids":["39075053"],"is_preprint":false},{"year":2025,"finding":"SIRT5-mediated desuccinylation of BCAT1 at K39 inhibits BCAT1's interaction with the E3 ubiquitin ligase CHIP, preventing BCAT1 proteasomal degradation. BCAT1 stabilization by SIRT5 promotes glioma cell proliferation and ferroptosis resistance. BCAT1 overexpression rescues the proliferation inhibition and ferroptosis sensitivity caused by SIRT5 knockdown.","method":"SIRT5 knockdown, desuccinylation site mapping (K39), Co-IP (BCAT1–CHIP interaction), ubiquitin-proteasome degradation assay, BCAT1 overexpression rescue, ferroptosis assays, proteomic and metabolomic analyses","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PTM site-specific (K39 desuccinylation) with interaction and rescue experiments, single lab","pmids":["40195331"],"is_preprint":false},{"year":2016,"finding":"DOT1L histone methyltransferase regulates BCAT1 expression through H3K79 methylation at the BCAT1 locus in breast cancer cells. BCAT1 was identified as a DOT1L target gene responsible for DOT1L-mediated sphere formation and cell migration.","method":"DOT1L knockdown and overexpression, H3K79 methylation ChIP at BCAT1 locus, BCAT1 expression analysis, sphere formation and migration assays","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP at BCAT1 locus linking H3K79me to transcription, functional knockdown assays, single lab","pmids":["26783998"],"is_preprint":false},{"year":2021,"finding":"BCAT1 depletion of αKG in lung cancer cells promotes expression of SOX2, a transcription factor regulating cancer cell stemness and metastasis. shRNA-mediated BCAT1 knockdown reduced αKG levels, increased SOX2 expression, reduced cell migration in vitro, and inhibited metastasis to distal organs in nude mice.","method":"shRNA knockdown of BCAT1, αKG quantification, SOX2 protein/mRNA measurement, in vitro migration assay, in vivo lung metastasis mouse model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolite measurement and downstream transcription factor linked by loss-of-function, in vivo validation, single lab","pmids":["34646394"],"is_preprint":false},{"year":2021,"finding":"BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy. Cisplatin upregulates BCAT1 expression; BCAT1 knockdown or leucine supplementation activates mTOR, inhibits autophagy, and increases cisplatin sensitivity. Chloroquine (autophagy inhibitor) phenocopies BCAT1 knockdown in vivo.","method":"BCAT1 knockdown, leucine/BCAA supplementation, mTOR signaling by Western blot, autophagy flux assays (LC3, p62), cisplatin sensitivity assays in vitro and in vivo, chloroquine inhibitor comparison","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary perturbations (KD, metabolite supplementation, pharmacological inhibitor) with in vivo confirmation, single lab","pmids":["33568627"],"is_preprint":false},{"year":2024,"finding":"BCAT1-mediated BCAA catabolism generates leucine and other BCAAs that sustain SHOC2 (a leucine-rich repeat protein) expression, thereby maintaining the SHOC2-RAS-ERK signaling pathway and TNBC cell survival. Eupalinolide B (EB) directly binds and inhibits BCAT1 (confirmed by ABPP, pull-down, CETSA, MST), reducing BCAA synthesis, suppressing SHOC2-RAS-ERK signaling, and inducing apoptosis.","method":"Activity-based protein profiling (ABPP), pull-down Western blot, CETSA, microscale thermophoresis (MST) for EB–BCAT1 binding; HPLC metabolite quantification; SHOC2/RAS/ERK Western blot; in vivo mouse tumor model","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — multiple direct binding assays for target identification, metabolite and pathway readouts, in vivo validation, single lab","pmids":["39490614"],"is_preprint":false},{"year":2024,"finding":"NOTCH1 directly controls BCAT1 expression by binding to the BCAT1 promoter (ChIP validation). In a murine T-ALL model, Bcat1-deficient cells showed defects in developing leukemia. BCAT1 depletion in T-ALL cells redirected leucine metabolism toward production of 3-hydroxy butyrate (3-HB), an endogenous HDAC inhibitor, causing altered protein acetylation and sensitization to DNA-damaging agents.","method":"ChIP (NOTCH1 binding to BCAT1 promoter), Bcat1 genetic KO in murine T-ALL retroviral model, metabolomics (leucine to 3-HB pathway), protein acetylation analysis, etoposide sensitivity assay, patient-derived xenograft model","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct ChIP for transcription factor binding, genetic KO in disease model, metabolic pathway tracing with functional consequence, PDX validation","pmids":["39234857"],"is_preprint":false},{"year":2024,"finding":"In CD4+ T cells, BCAT1 generates β-hydroxy β-methylbutyric acid (HMB) as a metabolite from cytosolic leucine catabolism through BCAT1 and HPD/HPDL enzymes. HMB upregulates HIF1α mRNA, activating the mTORC1–HIF1α pathway and increasing IL-17 production in Th17 cells. BCAT1 inhibition (Bi2 or L-β-homoleucine) or silencing attenuates IL-17 production; HMB supplementation rescues this effect. In vivo, BCAT1 blockade mitigated EAE severity.","method":"shRNA and pharmacological (Bi2, L-β-homoleucine) BCAT1 inhibition, HMB supplementation rescue, mTORC1–HIF1α pathway analysis (Western blot, RT-PCR), IL-17 ELISA, in vivo EAE mouse model","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis with metabolite rescue and in vivo disease model, single lab","pmids":["39085353"],"is_preprint":false},{"year":1999,"finding":"Overexpression of Bcat1/Eca39 in murine cells under serum deprivation leads to apoptotic cell death. The branched-chain keto acid α-ketoisocaproate (a product of BCAT1 leucine catabolism) can independently induce rapid apoptosis, suggesting BCAT1 promotes apoptosis via its metabolic products.","method":"Bcat1 overexpression in murine cells, cell viability assay under serum deprivation, α-ketoisocaproate treatment, apoptosis measurement","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct overexpression with apoptosis readout and metabolite treatment, single lab","pmids":["10471790"],"is_preprint":false},{"year":2004,"finding":"Exogenous BDNF upregulates BCATc (BCAT1) mRNA and protein in astrocytes of the rat dorsal lateral geniculate nucleus following visual cortex lesion, as identified by mRNA fingerprinting and confirmed by RT-PCR and in situ hybridization. This upregulation is cell-type specific (astrocytes rather than neurons in this lesion context), suggesting that BDNF-mediated neuroprotection involves modulation of glutamate metabolism by astrocytes via BCATc.","method":"mRNA fingerprinting, quantitative RT-PCR, in situ hybridization, immunohistochemistry in rat visual cortex lesion model with intraocular BDNF delivery","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multi-method confirmation of BDNF-regulated BCATc expression in defined cell type in vivo, single lab","pmids":["15233768"],"is_preprint":false},{"year":2022,"finding":"BCAT1 promotes osteoclast maturation through BCAA catabolism; enzymatic activity is required (enzymatically dead mutant abrogates maturation). BCAT1 loss or inhibition reduces mTORC1/S6K1 phosphorylation in osteoclast precursors, and ROS increase. mTORC1 stimulation rescues proliferation and reduces ROS in BCAT1 knockdown muscle cells, placing BCAT1 upstream of mTORC1–S6K1 signaling.","method":"shRNA-resistant BCAT1 cDNA rescue, enzymatically dead BCAT1 mutant, mTORC1/S6K1 phosphorylation by Western blot, ROS measurement, BCAT1 KD and mTORC1 activator (MYH1485) co-treatment in C2C12 muscle cells","journal":"BMC musculoskeletal disorders","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA-resistant rescue and mTOR activator epistasis, multiple readouts, single lab","pmids":["35562710"],"is_preprint":false},{"year":2022,"finding":"BCAT1 promotes AML by restricting αKG levels, leading to impaired αKG-dependent histone demethylase (KDM) activity, elevated H3K9me3, suppressed ATM expression, and impaired DNA damage repair. High BCAT1 AML cells have increased sensitivity to PARP inhibitors.","method":"BCAT1 KO/OE AML cell lines, αKG quantification, histone methylation (H3K9me3) by Western blot, ATM expression analysis, DNA damage assays, PARP inhibitor (BMN673) sensitivity in vivo and in vitro","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolite-to-epigenome-to-DNA repair pathway with genetic and pharmacological tools, single lab","pmids":["38340163"],"is_preprint":false},{"year":2024,"finding":"BCAT1 in AML engages in bidirectional substrate reactions consuming BCAAs; BCAT1-driven leucine and αKG production activates mTOR (~2-fold higher p-S6K) in primary CLL cells with high BCAT1 expression. Disruption of BCAT1 in CLL-derived cell lines substantially reduces growth ex vivo.","method":"Steady-state metabolomics, heavy isotope metabolic tracing in primary CLL cells, p-S6K quantification by Western blot, BCAT1 disruption in cell lines","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — isotope tracing and metabolomics with mTOR pathway validation, single lab","pmids":["39455853"],"is_preprint":false},{"year":2025,"finding":"In B cells, BCR/TLR9 costimulation highly induces BCAT1, which localizes to lysosomal membranes to support BCAA synthesis and mTORC1 activation. BCAT1 inhibition blunts BCR/TLR9-triggered (but not CD40L/IL-4-triggered) B cell proliferation, IL-10 expression, and lymphoma xenograft outgrowth.","method":"Transcriptomics, translatomics, and metabolomics of primary human B cells under distinct receptor stimuli; BCAT1 immunofluorescence localization to lysosomes; BCAT1 inhibition (pharmacological), BCR/TLR9 vs CD40L/IL-4 epistasis comparison; lymphoma xenograft model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiomic approach, direct subcellular localization, receptor-specific epistasis, in vivo xenograft validation","pmids":["40924473"],"is_preprint":false},{"year":2025,"finding":"BCAT1 activity in Müller cells is negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In diabetic conditions, elevated BCAT1 activity in Müller cells reduces intracellular αKG levels, increases H3K4me3 at promoters of inflammatory genes (IL-6, TNF-α), and boosts retinal inflammation. BCAT1 inhibitors reduce inflammatory gene expression and vascular leakage in diabetic retinas in vivo.","method":"ChIP (H3K4me3 at inflammatory gene promoters), kinase screening (Plk4→BCAT1 phospho-Thr333), BCAT1 inhibitors (BAY-069, ERG240) in diabetic mouse models, targeted metabolomics (αKG measurement in Müller cells), RNA-seq","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation site identified by kinase screening, ChIP for epigenetic mechanism, metabolomics, and in vivo pharmacology, single lab","pmids":["40530920"],"is_preprint":false},{"year":2024,"finding":"BCAT1 is directly regulated by P2X1-mediated signaling: ATP–P2X1 signaling upregulates PBX3, which transactivates BCAT1. P2X1 phosphorylation at S387 and T389 is required for its leukemia-promoting effects. P2X1 deletion impairs leukemia-initiating cell (LIC) self-renewal in AML, an effect mediated through the PBX3–BCAT1 pathway.","method":"P2X1 genetic deletion, P2X1 phospho-site mutants (S387A/T389A), ChIP/transactivation assay (PBX3 on BCAT1), AML mouse transplant model, human AML cell line knockdown","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis (P2X1→PBX3→BCAT1) with site-specific phospho mutants and in vivo transplant model, single lab","pmids":["36418376"],"is_preprint":false},{"year":2024,"finding":"BCAA/BCAT1 signaling enhances phosphorylation of CREB in TKI-resistant CML cells, which is required for maintenance of TKI-resistant leukemia. BCAT1 knockdown or BCAA deprivation abolishes CREB phosphorylation and leukemogenesis in a BCR-ABL T315I murine CML model.","method":"BCAT1 knockdown, BCAA stimulation in vitro, CREB phosphorylation by Western blot, BCR-ABLT315I murine transplant CML model, human TKI-resistant cell line proliferation assays","journal":"Cellular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis (BCAA→BCAT1→pCREB) with in vivo model, single lab","pmids":["39412615"],"is_preprint":false},{"year":2024,"finding":"Transcription factor EB (TFEB) directly regulates BCAT1 transcription to reprogram BCAA catabolism in pancreatic cancer cells. TFEB knockdown blocks BCAA catabolism by reducing BCAT1 expression, inhibiting proliferation and metastasis; combined BCAA deprivation and TFEB inhibition (eltrombopag) synergistically inhibits pancreatic cancer cell proliferation.","method":"TFEB knockdown (siRNA), BCAT1 mRNA/protein measurement, BCAA metabolomics, BCAA deprivation combined with eltrombopag treatment, proliferation and metastasis assays","journal":"Cell proliferation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — transcriptional regulation epistasis with metabolomics, single lab, no direct ChIP reported in abstract","pmids":["38938061"],"is_preprint":false},{"year":2024,"finding":"HuR RNA-binding protein directly interacts with BCAT1 mRNA, increasing its stability and translation, thereby upregulating BCAT1 protein and activating ERK5 signaling in castration-resistant prostate cancer. HuR KO or the HuR inhibitor KH-3 (which disrupts HuR–BCAT1 mRNA interaction) reduces BCAT1 expression and suppresses CRPC progression.","method":"HuR knockout (Cas9), mRNA half-life assay, RIP (HuR–BCAT1 mRNA), HuR inhibitor KH-3, ERK5 signaling by Western blot, xenograft tumor model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RIP for mRNA binding, mRNA stability assay, signaling pathway validation, in vivo confirmation, single lab","pmids":["38369471"],"is_preprint":false},{"year":2019,"finding":"miR-124-3p directly targets the BCAT1 mRNA 3'-UTR, resulting in BCAT1 upregulation when miR-124-3p is suppressed. DNMT1-mediated promoter hypermethylation silences miR-124-3p expression, establishing a DNMT1→miR-124-3p→BCAT1 axis that promotes ESCC proliferation and migration.","method":"miR-124-3p target validation (3'-UTR reporter/sequence analysis), DNMT1 knockdown and inhibition, miR-124-3p and BCAT1 expression in ESCC cell lines and tissues","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — epigenetic regulation axis with miRNA targeting, single lab, abstract does not explicitly state luciferase reporter confirmation of miR-124-3p/BCAT1 3'-UTR interaction","pmids":["31226958"],"is_preprint":false},{"year":2021,"finding":"BCAT1 activates the PI3K/AKT/mTOR pathway in gastric cancer cells, and pharmacological blockade with LY294002 reverses tumor growth induced by BCAT1 overexpression. BCAT1 promotes angiogenesis, invasion, and proliferation through this pathway.","method":"BCAT1 lentiviral overexpression/silencing, PI3K/AKT/mTOR pathway Western blot, LY294002 PI3K inhibitor rescue, xenograft model, angiogenesis assays","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — pharmacological epistasis with inhibitor rescue, in vivo xenograft, single lab","pmids":["34164393"],"is_preprint":false},{"year":2020,"finding":"BCATc (BCAT1) knockdown in TNBC cells significantly reduced insulin- and IGF-1-mediated proliferation, migration, and invasion. BCATc overexpression regulates proliferation through the PI3K/Akt axis while simultaneously attenuating the Ras/ERK pathway, ultimately increasing FOXO3a and Nrf2.","method":"BCATc siRNA knockdown and overexpression, IGF-1/insulin stimulation, PI3K/Akt and Ras/ERK pathway Western blot, FOXO3a and Nrf2 protein levels, proliferation and invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — gain- and loss-of-function with dual-pathway analysis, single lab","pmids":["32523652"],"is_preprint":false}],"current_model":"BCAT1 (BCATc) is a cytosolic branched-chain amino acid transaminase that catalyzes the first step of BCAA catabolism (transamination to αKG), thereby consuming αKG, generating glutamate and branched-chain α-keto acids (BCKAs), and regulating intracellular αKG homeostasis; through αKG depletion, BCAT1 limits TET-mediated DNA demethylation and αKG-dependent histone demethylation, causing epigenetic hypermethylation that mimics IDH mutation effects in cancer. BCAT1-derived BCKAs and leucine activate mTORC1 signaling to drive cell proliferation, mitochondrial biogenesis, and immune cell function, while BCAT1 also directly interacts with RhoC (promoting its GTPase activity via BCKA binding) and localizes to lysosomal membranes and mitotic structures where it exerts non-metabolic roles: a conserved CXXC redox motif controls cysteine sulfenylation, promotes Aurora kinase B localization to centromeres, and maintains mitotic fidelity. BCAT1 expression is transcriptionally controlled by c-Myc (direct promoter binding), NOTCH1 (direct promoter binding), DOT1L-mediated H3K79 methylation, STAT3 activation, and TFEB, and its protein stability is regulated by BCKDK-mediated phosphorylation (which increases activity and blocks STUB1/CHIP-mediated K48-ubiquitination and proteasomal degradation) and SIRT5-mediated desuccinylation at K39."},"narrative":{"mechanistic_narrative":"BCAT1 (BCATc) is a cytosolic branched-chain amino acid transaminase that initiates BCAA catabolism by transferring amino groups from BCAAs to α-ketoglutarate (αKG), thereby consuming αKG, generating glutamate and branched-chain α-keto acids (BCKAs), and serving as a central regulator of intracellular αKG homeostasis across cancer and immune contexts [PMID:23793099, PMID:29144447]. By depleting αKG, BCAT1 restrains αKG-dependent dioxygenases—reducing TET activity to cause DNA hypermethylation that mimics IDH mutation [PMID:29144447], impairing KDM histone demethylases to elevate H3K9me3 and suppress ATM-dependent DNA repair [PMID:38340163], and reciprocally driving promoter H3K4me3 at inflammatory genes [PMID:40530920]—and stabilizing HIF1α by limiting EGLN1 activity [PMID:29144447]. Its catabolic products feed anabolic signaling: BCKA and leucine sustain mitochondrial metabolism, nucleotide biosynthesis, and mTORC1 activity, with αKG supplementation producing synthetic lethality in BCAT1-null glioblastoma [PMID:35499760, PMID:24847056]. BCAT1 also exerts catalysis-independent functions through a conserved CXXC redox motif that metabolizes H2O2, buffers ROS, and—during mitosis—promotes Aurora kinase B localization to centromeres to maintain chromosome segregation fidelity [PMID:36260995, PMID:35453368]. Beyond transamination, BCAT1 directly binds RhoC to elevate its GTPase activity, an interaction reinforced by BCKA binding to RhoC, thereby promoting cell motility [PMID:37337119]. BCAT1 expression is driven transcriptionally by c-Myc and NOTCH1 promoter binding and by DOT1L-mediated H3K79 methylation [PMID:23758864, PMID:39234857, PMID:26783998], while its protein stability is controlled by BCKDK phosphorylation and SIRT5 desuccinylation that antagonize STUB1/CHIP-mediated K48 ubiquitination and proteasomal degradation [PMID:38621458, PMID:39075053, PMID:40195331]. Through these axes BCAT1 supports proliferation, stemness, and therapy resistance in multiple cancers, lymphocyte and osteoclast function, and is induced in neurons and astrocytes consistent with a role in glutamate metabolism [PMID:15329886, PMID:15233768, PMID:39234857, PMID:40924473].","teleology":[{"year":1999,"claim":"Established that BCAT1 metabolic products themselves can drive cell fate, showing that a keto-acid product of leucine catabolism induces apoptosis.","evidence":"Bcat1/Eca39 overexpression in murine cells under serum deprivation with α-ketoisocaproate treatment","pmids":["10471790"],"confidence":"Medium","gaps":["Mechanism linking keto-acid to apoptotic machinery not defined","Single overexpression system without endogenous validation"]},{"year":2004,"claim":"Defined the in vivo expression pattern of BCATc in neural tissue, linking it to glutamate metabolism in distinct neuronal and astrocytic compartments.","evidence":"Immunohistochemistry across rat brain regions; mRNA fingerprinting and in situ hybridization in a BDNF-treated visual cortex lesion model","pmids":["15329886","15233768"],"confidence":"Medium","gaps":["Functional consequence of neuronal vs astrocytic localization not tested","No direct measurement of neurotransmitter pools"]},{"year":2013,"claim":"Identified BCAT1 as a driver of BCAA catabolism and glutamate excretion in glioma and showed its expression is governed by αKG availability and antagonized by mutant IDH1, linking it to the IDH oncometabolite axis; concurrently established c-Myc as a direct transcriptional activator.","evidence":"shRNA knockdown and xenografts in glioma; ectopic mutant IDH1 in astrocytes; ChIP and luciferase reporter for c-Myc on the BCAT1 promoter","pmids":["23793099","23758864"],"confidence":"High","gaps":["Direct epigenetic consequences of αKG depletion not yet measured here","Mechanism by which IDH1 mutation suppresses BCAT1 not resolved"]},{"year":2014,"claim":"Connected BCAT1 to immune signaling by showing TCR-induced BCATc lowers intracellular leucine to restrain mTORC1 and glycolysis in CD4+ T cells, with NFAT placed upstream.","evidence":"BCATc knockout mouse, leucine transamination assays, mTORC1 phospho-readouts, cyclosporin A inhibition","pmids":["24847056"],"confidence":"High","gaps":["Whether leucine depletion is the sole mTORC1-limiting mechanism unclear","Context-dependence relative to anabolic roles in cancer not reconciled"]},{"year":2017,"claim":"Established the core mechanistic principle that BCAT1 controls intracellular αKG to govern HIF1α stability and TET-dependent DNA methylation, mimicking IDH mutation, and links BCAA catabolism to mitochondrial biogenesis via mTOR.","evidence":"BCAT1 gain/loss in leukemia cells with metabolomics, HIF1α/TET assays, DNA methylation profiling; breast cancer mTOR/AMPK/SIRT1 analysis","pmids":["29144447","28235484"],"confidence":"High","gaps":["Generality of αKG-mediated epigenetic effects across tissues not yet shown","mTOR activation mechanism (metabolite vs other) not fully defined"]},{"year":2016,"claim":"Identified epigenetic transcriptional control of BCAT1 via DOT1L-mediated H3K79 methylation in breast cancer.","evidence":"DOT1L knockdown/overexpression, H3K79me ChIP at BCAT1 locus, sphere/migration assays","pmids":["26783998"],"confidence":"Medium","gaps":["Direct vs indirect DOT1L effect on BCAT1 not separated","Single lineage context"]},{"year":2020,"claim":"Expanded BCAT1 regulation to additional transcriptional and post-transcriptional inputs and to stromal supply roles, showing TGF-β/SMAD5 control in fibroblasts and an RNA-binding/ER-stress axis driving autophagy.","evidence":"TGF-β/SMAD5 perturbation and isotope tracing in CAFs; ZNF423–BCAT1 mRNA pulldown and BCAT1–IRE1 Co-IP in hypoxic PASMCs","pmids":["32694827","32938905"],"confidence":"Medium","gaps":["Direct SMAD5 binding to BCAT1 not shown","Non-metabolic IRE1 interaction lacks structural detail"]},{"year":2021,"claim":"Broadened BCAT1's downstream signaling outputs and physiological roles, linking it to mTOR-driven autophagy and chemoresistance, PI3K/AKT and Ras/ERK signaling, SOX2-dependent stemness, and enzyme-dependent osteoclast maturation.","evidence":"Knockdown/overexpression with pathway Western blots and inhibitors (LY294002, chloroquine), αKG/SOX2 quantification, catalytic-dead BCAT1 mutants and gabapentin in osteoclast/muscle systems, in vivo models","pmids":["33568627","34164393","32523652","34646394","35760874"],"confidence":"Medium","gaps":["Whether mTOR/PI3K effects are direct or metabolite-driven not always resolved","Tissue-specific reconciliation of pro- vs anti-mTOR effects pending"]},{"year":2022,"claim":"Revealed catalysis-independent functions of BCAT1, defining the CXXC redox motif as a peroxide-metabolizing antioxidant module that controls mitotic Aurora B localization and chromosome segregation, and demonstrating αKG synthetic lethality and αKG-dependent epigenetic/DNA-repair control.","evidence":"CXXC separation-of-function rescue with live imaging and sulfenylation assays; in vitro H2O2 metabolism with purified protein; metabolic synthetic-lethal screens with BCKA/αKG rescue; H3K9me3/ATM/PARP-inhibitor analyses","pmids":["36260995","35453368","35499760","38340163","35562710"],"confidence":"High","gaps":["Molecular basis of BCAT1–Aurora B coupling unknown","How redox and metabolic functions are partitioned in vivo unresolved"]},{"year":2023,"claim":"Demonstrated a direct non-metabolic protein interaction by which BCAT1 binds RhoC to elevate its GTPase activity, with BCKA acting as a direct RhoC ligand, and identified a gain-of-function mutation enhancing this axis.","evidence":"Co-IP, RhoC GTPase and BCKA-RhoC binding assays, BCAT1 E61A mutant and KO rescue, in vivo metastasis model","pmids":["37337119"],"confidence":"High","gaps":["Structural interface of BCAT1–RhoC binding not defined","Reciprocal validation of interaction in additional systems limited"]},{"year":2024,"claim":"Mapped the post-translational and transcriptional control network stabilizing BCAT1—BCKDK phosphorylation and STUB1/CHIP ubiquitination at defined sites—and added NOTCH1, TFEB, PBX3, HuR, and CREB-linked inputs while detailing metabolite-driven immune and leukemic phenotypes.","evidence":"Phospho/ubiquitin site mapping and Co-IP for BCKDK–STUB1–BCAT1; ChIP for NOTCH1; TFEB/PBX3/HuR perturbations with RIP and metabolomics; metabolite tracing to 3-HB and HMB with EAE, AML, CML, and B-cell/lymphoma models","pmids":["38621458","39075053","39234857","38938061","36418376","38369471","39085353","39455853","39412615"],"confidence":"Medium","gaps":["Hierarchy and cross-talk among multiple regulators not integrated","Several transcriptional links lack direct promoter-binding evidence"]},{"year":2025,"claim":"Linked subcellular localization and an additional PTM to BCAT1 function, showing lysosomal-membrane localization supporting BCAA synthesis and mTORC1 in B cells, SIRT5 desuccinylation at K39 stabilizing BCAT1 against CHIP degradation, and Plk4 phosphorylation negatively regulating its αKG-dependent epigenetic activity.","evidence":"Multiomics and immunofluorescence in primary B cells; SIRT5 knockdown with K39 desuccinylation mapping and CHIP Co-IP; Plk4 phospho-Thr333 mapping with ChIP and αKG metabolomics in Müller cells","pmids":["40924473","40195331","40530920"],"confidence":"Medium","gaps":["Mechanism of lysosomal recruitment unknown","Interplay between SIRT5, BCKDK, and CHIP on the same protein not jointly tested"]},{"year":null,"claim":"How BCAT1's metabolic, redox/CXXC, and direct protein-interaction (RhoC, Aurora B, IRE1) functions are coordinated and partitioned within a cell, and what determines its divergent mTORC1 outcomes across cell types, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating catalytic and non-catalytic domains","Spatial coordination of cytosolic, lysosomal, and mitotic pools undefined","Context determinants of pro- vs anti-mTORC1 activity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,3,10,11]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[27]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,10]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,25,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,9,34]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,21,27]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[13,14,15]}],"complexes":[],"partners":["RHOC","STUB1","BCKDK","SIRT5","IRE1","ZNF423","HUR","PLK4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P54687","full_name":"Branched-chain-amino-acid aminotransferase, cytosolic","aliases":[],"length_aa":386,"mass_kda":43.0,"function":"Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P54687/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCAT1","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCAT1","total_profiled":1310},"omim":[{"mim_id":"607897","title":"MUSASHI RNA BINDING PROTEIN 2; MSI2","url":"https://www.omim.org/entry/607897"},{"mim_id":"601626","title":"LEUKEMIA, ACUTE MYELOID; AML","url":"https://www.omim.org/entry/601626"},{"mim_id":"113530","title":"BRANCHED-CHAIN AMINOTRANSFERASE 2; BCAT2","url":"https://www.omim.org/entry/113530"},{"mim_id":"113520","title":"BRANCHED-CHAIN AMINOTRANSFERASE 1; BCAT1","url":"https://www.omim.org/entry/113520"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"pancreas","ntpm":54.8}],"url":"https://www.proteinatlas.org/search/BCAT1"},"hgnc":{"alias_symbol":["BCATc"],"prev_symbol":["BCT1"]},"alphafold":{"accession":"P54687","domains":[{"cath_id":"3.30.470.10","chopping":"26-189","consensus_level":"high","plddt":98.2441,"start":26,"end":189},{"cath_id":"3.20.10.10","chopping":"201-373","consensus_level":"high","plddt":97.9701,"start":201,"end":373}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54687","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54687-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54687-F1-predicted_aligned_error_v6.png","plddt_mean":94.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCAT1","jax_strain_url":"https://www.jax.org/strain/search?query=BCAT1"},"sequence":{"accession":"P54687","fasta_url":"https://rest.uniprot.org/uniprotkb/P54687.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54687/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54687"}},"corpus_meta":[{"pmid":"23793099","id":"PMC_23793099","title":"BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23793099","citation_count":406,"is_preprint":false},{"pmid":"29144447","id":"PMC_29144447","title":"BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29144447","citation_count":308,"is_preprint":false},{"pmid":"28235484","id":"PMC_28235484","title":"Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28235484","citation_count":174,"is_preprint":false},{"pmid":"32694827","id":"PMC_32694827","title":"Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours.","date":"2020","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694827","citation_count":169,"is_preprint":false},{"pmid":"23758864","id":"PMC_23758864","title":"Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23758864","citation_count":128,"is_preprint":false},{"pmid":"26445409","id":"PMC_26445409","title":"Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26445409","citation_count":104,"is_preprint":false},{"pmid":"26372729","id":"PMC_26372729","title":"BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26372729","citation_count":92,"is_preprint":false},{"pmid":"26765125","id":"PMC_26765125","title":"A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia.","date":"2016","source":"Clinical and translational gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26765125","citation_count":89,"is_preprint":false},{"pmid":"27726312","id":"PMC_27726312","title":"A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27726312","citation_count":82,"is_preprint":false},{"pmid":"24847056","id":"PMC_24847056","title":"Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24847056","citation_count":81,"is_preprint":false},{"pmid":"33568627","id":"PMC_33568627","title":"BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33568627","citation_count":80,"is_preprint":false},{"pmid":"15329886","id":"PMC_15329886","title":"Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus.","date":"2004","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15329886","citation_count":74,"is_preprint":false},{"pmid":"37337119","id":"PMC_37337119","title":"Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37337119","citation_count":70,"is_preprint":false},{"pmid":"34164393","id":"PMC_34164393","title":"BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34164393","citation_count":54,"is_preprint":false},{"pmid":"26783998","id":"PMC_26783998","title":"DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.","date":"2016","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/26783998","citation_count":48,"is_preprint":false},{"pmid":"30230527","id":"PMC_30230527","title":"LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/ BCAT1 axis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30230527","citation_count":47,"is_preprint":false},{"pmid":"10471790","id":"PMC_10471790","title":"Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471790","citation_count":46,"is_preprint":false},{"pmid":"35499760","id":"PMC_35499760","title":"Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35499760","citation_count":45,"is_preprint":false},{"pmid":"31226958","id":"PMC_31226958","title":"The role of DNMT1/hsa-miR-124-3p/BCAT1 pathway in regulating growth and invasion of esophageal squamous cell carcinoma.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31226958","citation_count":42,"is_preprint":false},{"pmid":"27698837","id":"PMC_27698837","title":"BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27698837","citation_count":39,"is_preprint":false},{"pmid":"35760874","id":"PMC_35760874","title":"BCAT1 promotes osteoclast maturation by regulating branched-chain amino acid metabolism.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35760874","citation_count":39,"is_preprint":false},{"pmid":"32689462","id":"PMC_32689462","title":"Structure, function and regulation of the cyanobacterial high-affinity bicarbonate transporter, BCT1.","date":"2002","source":"Functional plant biology : FPB","url":"https://pubmed.ncbi.nlm.nih.gov/32689462","citation_count":37,"is_preprint":false},{"pmid":"34646394","id":"PMC_34646394","title":"Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34646394","citation_count":36,"is_preprint":false},{"pmid":"28052414","id":"PMC_28052414","title":"MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.","date":"2017","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28052414","citation_count":34,"is_preprint":false},{"pmid":"35326233","id":"PMC_35326233","title":"Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35326233","citation_count":33,"is_preprint":false},{"pmid":"35000264","id":"PMC_35000264","title":"Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35000264","citation_count":31,"is_preprint":false},{"pmid":"36260995","id":"PMC_36260995","title":"BCAT1 redox function maintains mitotic fidelity.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36260995","citation_count":30,"is_preprint":false},{"pmid":"31949641","id":"PMC_31949641","title":"BCAT1 promotes proliferation of endometrial cancer cells through reprogrammed BCAA metabolism.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31949641","citation_count":30,"is_preprint":false},{"pmid":"32958500","id":"PMC_32958500","title":"Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC).","date":"2020","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32958500","citation_count":30,"is_preprint":false},{"pmid":"32425554","id":"PMC_32425554","title":"BCAT1 Overexpression Promotes Proliferation, Invasion, and Wnt Signaling in Non-Small Cell Lung Cancers.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32425554","citation_count":29,"is_preprint":false},{"pmid":"33484341","id":"PMC_33484341","title":"Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1.","date":"2021","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33484341","citation_count":29,"is_preprint":false},{"pmid":"39085353","id":"PMC_39085353","title":"Inhibition of BCAT1-mediated cytosolic leucine metabolism regulates Th17 responses via the mTORC1-HIF1α pathway.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39085353","citation_count":28,"is_preprint":false},{"pmid":"33478584","id":"PMC_33478584","title":"Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33478584","citation_count":27,"is_preprint":false},{"pmid":"34984849","id":"PMC_34984849","title":"BCAT1: A risk factor in multiple cancers based on a pan-cancer analysis.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34984849","citation_count":25,"is_preprint":false},{"pmid":"18074675","id":"PMC_18074675","title":"Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12.","date":"2007","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/18074675","citation_count":23,"is_preprint":false},{"pmid":"32938905","id":"PMC_32938905","title":"BCAT1 binds the RNA-binding protein ZNF423 to activate autophagy via the IRE1-XBP-1-RIDD axis in hypoxic PASMCs.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32938905","citation_count":22,"is_preprint":false},{"pmid":"38871197","id":"PMC_38871197","title":"BCAT1 alleviates early brain injury by inhibiting ferroptosis through PI3K/AKT/mTOR/GPX4 pathway after subarachnoid hemorrhage.","date":"2024","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38871197","citation_count":22,"is_preprint":false},{"pmid":"30265706","id":"PMC_30265706","title":"Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30265706","citation_count":22,"is_preprint":false},{"pmid":"33760210","id":"PMC_33760210","title":"BCAT1 overexpression regulates proliferation and c‑Myc/GLUT1 signaling in head and neck squamous cell carcinoma.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33760210","citation_count":20,"is_preprint":false},{"pmid":"32523652","id":"PMC_32523652","title":"BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/32523652","citation_count":19,"is_preprint":false},{"pmid":"35453368","id":"PMC_35453368","title":"The BCAT1 CXXC Motif Provides Protection against ROS in Acute Myeloid Leukaemia Cells.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35453368","citation_count":19,"is_preprint":false},{"pmid":"33744853","id":"PMC_33744853","title":"Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33744853","citation_count":19,"is_preprint":false},{"pmid":"32855634","id":"PMC_32855634","title":"Silencing of Long Noncoding RNA LINC00324 Interacts with MicroRNA-3200-5p to Attenuate the Tumorigenesis of Gastric Cancer via Regulating BCAT1.","date":"2020","source":"Gastroenterology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32855634","citation_count":19,"is_preprint":false},{"pmid":"39490614","id":"PMC_39490614","title":"Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39490614","citation_count":18,"is_preprint":false},{"pmid":"34249421","id":"PMC_34249421","title":"BCAT1 knockdown-mediated suppression of melanoma cell proliferation and migration is associated with reduced oxidative phosphorylation.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34249421","citation_count":18,"is_preprint":false},{"pmid":"36644500","id":"PMC_36644500","title":"The emerging role of the branched chain aminotransferases, BCATc and BCATm, for anti-tumor T-cell immunity.","date":"2023","source":"Immunometabolism (Cobham, Surrey)","url":"https://pubmed.ncbi.nlm.nih.gov/36644500","citation_count":17,"is_preprint":false},{"pmid":"36386234","id":"PMC_36386234","title":"BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36386234","citation_count":17,"is_preprint":false},{"pmid":"32269179","id":"PMC_32269179","title":"USF1-mediated upregulation of lncRNA GAS6-AS2 facilitates osteosarcoma progression through miR-934/BCAT1 axis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32269179","citation_count":17,"is_preprint":false},{"pmid":"32273770","id":"PMC_32273770","title":"LINC00963 Confers Oncogenic Properties in Glioma by Regulating the miR-506/BCAT1 Axis.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32273770","citation_count":17,"is_preprint":false},{"pmid":"34370878","id":"PMC_34370878","title":"Long non-coding RNA TMPO-AS1 facilitates the progression of colorectal cancer cells via sponging miR-98-5p to upregulate BCAT1 expression.","date":"2021","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34370878","citation_count":16,"is_preprint":false},{"pmid":"30427175","id":"PMC_30427175","title":"Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1).","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30427175","citation_count":16,"is_preprint":false},{"pmid":"35562710","id":"PMC_35562710","title":"Impaired expression of BCAT1 relates to muscle atrophy of mouse model of sarcopenia.","date":"2022","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35562710","citation_count":15,"is_preprint":false},{"pmid":"31788061","id":"PMC_31788061","title":"Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31788061","citation_count":15,"is_preprint":false},{"pmid":"34109436","id":"PMC_34109436","title":"Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine‑resistant myeloid leukemia cells.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34109436","citation_count":15,"is_preprint":false},{"pmid":"35253733","id":"PMC_35253733","title":"Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients.","date":"2022","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35253733","citation_count":15,"is_preprint":false},{"pmid":"28416735","id":"PMC_28416735","title":"Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28416735","citation_count":15,"is_preprint":false},{"pmid":"35290664","id":"PMC_35290664","title":"Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.","date":"2022","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35290664","citation_count":15,"is_preprint":false},{"pmid":"38621458","id":"PMC_38621458","title":"Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38621458","citation_count":14,"is_preprint":false},{"pmid":"34329662","id":"PMC_34329662","title":"Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells.","date":"2021","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34329662","citation_count":14,"is_preprint":false},{"pmid":"15233768","id":"PMC_15233768","title":"Intraocular delivery of BDNF following visual cortex lesion upregulates cytosolic branched chain aminotransferase (BCATc) in the rat dorsal lateral geniculate nucleus.","date":"2004","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15233768","citation_count":14,"is_preprint":false},{"pmid":"35776379","id":"PMC_35776379","title":"Circular RNA VPS18 Promotes Glioblastoma Progression by Regulating miR-1229-3p/BCAT1 Axis.","date":"2022","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/35776379","citation_count":13,"is_preprint":false},{"pmid":"35318805","id":"PMC_35318805","title":"Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35318805","citation_count":13,"is_preprint":false},{"pmid":"32630973","id":"PMC_32630973","title":"Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA.","date":"2017","source":"The journal of applied laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32630973","citation_count":13,"is_preprint":false},{"pmid":"27626306","id":"PMC_27626306","title":"Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626306","citation_count":13,"is_preprint":false},{"pmid":"36418376","id":"PMC_36418376","title":"P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36418376","citation_count":12,"is_preprint":false},{"pmid":"38938061","id":"PMC_38938061","title":"Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1.","date":"2024","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/38938061","citation_count":12,"is_preprint":false},{"pmid":"14563018","id":"PMC_14563018","title":"Lrmp and Bcat1 are candidates for the type I diabetes susceptibility locus Idd6.","date":"2003","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/14563018","citation_count":12,"is_preprint":false},{"pmid":"36111572","id":"PMC_36111572","title":"BCAT1 promotes lung adenocarcinoma progression through enhanced mitochondrial function and NF-κB pathway activation.","date":"2022","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/36111572","citation_count":12,"is_preprint":false},{"pmid":"38644767","id":"PMC_38644767","title":"BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas.","date":"2024","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/38644767","citation_count":11,"is_preprint":false},{"pmid":"17150414","id":"PMC_17150414","title":"Expression of cytosolic branched chain aminotransferase (BCATc) mRNA in the developing mouse brain.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17150414","citation_count":11,"is_preprint":false},{"pmid":"30113684","id":"PMC_30113684","title":"Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.","date":"2019","source":"Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/30113684","citation_count":11,"is_preprint":false},{"pmid":"16828066","id":"PMC_16828066","title":"Cytosolic branched chain aminotransferase (BCATc) mRNA is up-regulated in restricted brain areas of BDNF transgenic mice.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16828066","citation_count":10,"is_preprint":false},{"pmid":"37705956","id":"PMC_37705956","title":"LncRNA THUMPD3-AS1 promotes invasion and EMT in gastric cancer by regulating the miR-1297/BCAT1 pathway.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37705956","citation_count":10,"is_preprint":false},{"pmid":"38776254","id":"PMC_38776254","title":"Engineering the cyanobacterial ATP-driven BCT1 bicarbonate transporter for functional targeting to C3 plant chloroplasts.","date":"2024","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/38776254","citation_count":10,"is_preprint":false},{"pmid":"30310175","id":"PMC_30310175","title":"BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor.","date":"2018","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/30310175","citation_count":10,"is_preprint":false},{"pmid":"36123616","id":"PMC_36123616","title":"Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer.","date":"2022","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/36123616","citation_count":10,"is_preprint":false},{"pmid":"39234857","id":"PMC_39234857","title":"BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1.","date":"2025","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/39234857","citation_count":8,"is_preprint":false},{"pmid":"36182869","id":"PMC_36182869","title":"The proatherosclerotic function of BCAT1 in atherosclerosis development of aged-apolipoprotein E-deficient mice.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36182869","citation_count":8,"is_preprint":false},{"pmid":"30378334","id":"PMC_30378334","title":"[The Expression and Significance of c-myc and bcat1 in Cervical Cancer].","date":"2018","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/30378334","citation_count":8,"is_preprint":false},{"pmid":"40195331","id":"PMC_40195331","title":"SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40195331","citation_count":7,"is_preprint":false},{"pmid":"38235619","id":"PMC_38235619","title":"LncRNA PSMB8-AS1 increases glioma malignancy via the miR-382-3p/BCAT1 axis.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38235619","citation_count":7,"is_preprint":false},{"pmid":"40530920","id":"PMC_40530920","title":"BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/40530920","citation_count":6,"is_preprint":false},{"pmid":"39455853","id":"PMC_39455853","title":"Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39455853","citation_count":6,"is_preprint":false},{"pmid":"38340163","id":"PMC_38340163","title":"High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.","date":"2024","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38340163","citation_count":6,"is_preprint":false},{"pmid":"37344908","id":"PMC_37344908","title":"BCAT1 controls embryonic neural stem cells proliferation and differentiation in the upper layer neurons.","date":"2023","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/37344908","citation_count":6,"is_preprint":false},{"pmid":"39412615","id":"PMC_39412615","title":"BCAT1 contributes to the development of TKI-resistant CML.","date":"2024","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/39412615","citation_count":6,"is_preprint":false},{"pmid":"33500319","id":"PMC_33500319","title":"Variables Associated with Detection of Methylated BCAT1 or IKZF1 in Blood from Patients Without Colonoscopically Evident Colorectal Cancer.","date":"2021","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33500319","citation_count":6,"is_preprint":false},{"pmid":"39075053","id":"PMC_39075053","title":"CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39075053","citation_count":5,"is_preprint":false},{"pmid":"39356334","id":"PMC_39356334","title":"Inhibition of BCAT1 expression improves recurrent miscarriage by regulating cellular dysfunction and inflammation of trophoblasts.","date":"2024","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/39356334","citation_count":5,"is_preprint":false},{"pmid":"38369471","id":"PMC_38369471","title":"HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38369471","citation_count":5,"is_preprint":false},{"pmid":"31465797","id":"PMC_31465797","title":"BCAT1 and BCAT2 disruption in CHO cells has cell line-dependent effects.","date":"2019","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31465797","citation_count":4,"is_preprint":false},{"pmid":"35788291","id":"PMC_35788291","title":"Driving with Both Feet: Supplementing AKG While Inhibiting BCAT1 Leads to Synthetic Lethality in GBM.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35788291","citation_count":4,"is_preprint":false},{"pmid":"39324007","id":"PMC_39324007","title":"Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39324007","citation_count":4,"is_preprint":false},{"pmid":"39056279","id":"PMC_39056279","title":"BCAT1 promotes cell proliferation, migration, and invasion via the PI3K-Akt signaling pathway in oral squamous cell carcinoma.","date":"2024","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39056279","citation_count":4,"is_preprint":false},{"pmid":"30069041","id":"PMC_30069041","title":"Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30069041","citation_count":4,"is_preprint":false},{"pmid":"37591221","id":"PMC_37591221","title":"MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1.","date":"2023","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37591221","citation_count":3,"is_preprint":false},{"pmid":"37700640","id":"PMC_37700640","title":"Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.","date":"2023","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37700640","citation_count":3,"is_preprint":false},{"pmid":"40005214","id":"PMC_40005214","title":"Design, Synthesis and Biological Activity Study of γ-Aminobutyric Acid (GABA) Derivatives Containing Bridged Bicyclic Skeletons as BCAT1 Inhibitors.","date":"2025","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40005214","citation_count":3,"is_preprint":false},{"pmid":"40924473","id":"PMC_40924473","title":"Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40924473","citation_count":2,"is_preprint":false},{"pmid":"39154541","id":"PMC_39154541","title":"A blood test measuring DNA methylation of BCAT1 and IKZF1 for detection of lung adenocarcinoma.","date":"2024","source":"Cancer treatment and research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39154541","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54670,"output_tokens":10550,"usd":0.16113,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21335,"output_tokens":5203,"usd":0.118375,"stage2_stop_reason":"end_turn"},"total_usd":0.279505,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"BCAT1 initiates catabolism of branched-chain amino acids (BCAAs) in glioblastoma; suppression of BCAT1 in glioma cell lines blocked glutamate excretion and reduced proliferation and invasiveness in vitro, and decreased tumor growth in xenograft models. BCAT1 expression was dependent on α-ketoglutarate substrate concentration and could be suppressed by ectopic overexpression of mutant IDH1 in immortalized human astrocytes, linking IDH1 function to BCAT1 expression.\",\n      \"method\": \"shRNA knockdown in glioma cell lines, xenograft mouse model, ectopic mutant IDH1 overexpression in astrocytes, glutamate excretion assay\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, epistasis with IDH1, replicated across cell lines and xenograft model\",\n      \"pmids\": [\"23793099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCAT1 is a critical regulator of intracellular α-ketoglutarate (αKG) homeostasis in AML stem cells: it transfers α-amino groups from BCAAs to αKG, consuming αKG. Knockdown of BCAT1 caused αKG accumulation, leading to EGLN1-mediated HIF1α protein degradation and growth/survival defects. Overexpression of BCAT1 decreased intracellular αKG and caused DNA hypermethylation through reduced TET enzyme activity, mimicking IDH mutation effects.\",\n      \"method\": \"BCAT1 knockdown and overexpression in leukemia cells, high-resolution proteomics, intracellular metabolite measurements (αKG), HIF1α protein level analysis, TET activity assay, DNA methylation profiling\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods (metabolomics, protein degradation assays, epigenomic profiling), gain-of-function and loss-of-function in same study\",\n      \"pmids\": [\"29144447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCAT1 promotes mitochondrial biogenesis, ATP production, and represses mitochondrial ROS in breast cancer cells by activating mTOR (but not AMPK or SIRT1) signaling. Knockdown of BCAT1 repressed cell growth and colony formation.\",\n      \"method\": \"BCAT1 knockdown and overexpression in breast cancer cells, mTOR/AMPK/SIRT1 pathway Western blot, mitochondrial biogenesis and ATP assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single lab, multiple orthogonal functional assays but no in vivo confirmation\",\n      \"pmids\": [\"28235484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TCR activation of CD4+ T cells triggers expression of cytosolic BCATc (BCAT1), which increases leucine transamination and lowers intracellular leucine. BCATc(-/-) T cells have higher intracellular leucine, elevated mTORC1 activation (increased phospho-S6 and 4EBP-1), and higher glycolytic rates than wild-type T cells. BCATc induction by TCR is blocked by the calcineurin/NFAT inhibitor cyclosporin A, placing NFAT upstream of BCAT1 expression.\",\n      \"method\": \"BCATc knockout mouse (BCATc-/-), leucine transamination assays, mTORC1 phosphorylation (S6, 4EBP-1) by Western blot, glycolysis measurements, cyclosporin A pharmacological inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO mouse model with biochemical pathway validation, multiple orthogonal readouts\",\n      \"pmids\": [\"24847056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"c-Myc directly binds to the c-Myc binding site in the BCAT1 promoter and upregulates BCAT1 expression in nasopharyngeal carcinoma (NPC). Knockdown of c-Myc downregulates BCAT1, and BCAT1 knockdown reduces NPC cell proliferation, migration, and invasion.\",\n      \"method\": \"ChIP assay (c-Myc binding to BCAT1 promoter), luciferase reporter assay, c-Myc siRNA knockdown, BCAT1 siRNA knockdown, colony formation, migration and invasion assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct ChIP and luciferase reporter validation of c-Myc→BCAT1 promoter binding, supported by siRNA functional assays\",\n      \"pmids\": [\"23758864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In pancreatic cancer stroma, TGF-β–SMAD5 axis directly targets BCAT1 in cancer-associated fibroblasts (CAFs), dictating internalization of extracellular matrix to supply amino-acid precursors for BCKA secretion, which is then utilized by adjacent cancer cells.\",\n      \"method\": \"TGF-β–SMAD5 pathway perturbation in CAFs, BCAT1 expression measurement, metabolic flux analysis (isotope tracing), circulating tumor cells and PDAC tissue slice validation\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis with TGF-β/SMAD5 and metabolic tracing, single lab but multiple methods including patient-derived material\",\n      \"pmids\": [\"32694827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BCATc (BCAT1) is expressed exclusively in neurons in the adult rat brain. In glutamatergic neurons (e.g., granule cells of cerebellum and dentate gyrus), BCATc localizes to axons and nerve terminals; in GABAergic neurons (Purkinje cells, hippocampal pyramidal basket cells), it is concentrated in cell bodies. BCATc is strongly expressed in the mossy fiber pathway. This localization supports a role in modulating glutamate availability for neurotransmitter release or GABA synthesis.\",\n      \"method\": \"Immunohistochemistry in rat brain sections, cell-type specific localization in neuronal subtypes\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct immunohistochemical localization across multiple brain regions and cell types, single lab\",\n      \"pmids\": [\"15329886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 localizes to mitotic structures and has a non-metabolic function as a mitotic regulator. The BCAT1 CXXC redox motif controls cysteine sulfenylation specifically in mitotic cells, promotes Aurora kinase B localization to centromeres, and is required for accurate chromosome segregation in cancer and iPSC cells. Loss of BCAT1 causes mitotic errors; rescue requires the intact CXXC motif, not catalytic BCAA transaminase activity.\",\n      \"method\": \"Gene knockout and rescue with CXXC mutant vs. wild-type BCAT1, live-cell imaging of mitotic structures, immunofluorescence of Aurora B at centromeres, cysteine sulfenylation assay, human cerebral organoid and mouse syngraft tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic rescue with separation-of-function mutant (CXXC), multiple orthogonal methods, in vitro and in vivo validation\",\n      \"pmids\": [\"36260995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The BCAT1 CXXC motif can metabolize H2O2 in vitro (novel antioxidant activity), whereas CXXC-mutant BCAT1 or wild-type BCAT2 cannot. In AML cells, overexpression of wild-type BCAT1 reduces intracellular ROS compared to CXXS mutant, reduces myeloid differentiation markers, and protects against apoptosis, implicating the BCAT1 CXXC motif in redox buffering and myeloid differentiation block.\",\n      \"method\": \"In vitro H2O2 metabolism assay with purified BCAT1 protein (WT vs. CXXC mutant), intracellular ROS measurement in U937 AML cells, flow cytometry for myeloid markers and apoptosis\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with purified protein and mutagenesis, cell-based validation with WT vs. mutant rescue\",\n      \"pmids\": [\"35453368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCAT1 directly interacts with RhoC (identified by co-IP/pulldown), leading to elevation of RhoC GTPase activity. Additionally, the BCAA-derived metabolite branched-chain α-keto acid (BCKA) directly binds to RhoC and promotes its activity. A gain-of-function BCAT1 E61A mutation (enriched in gastric cancer) confers higher enzymatic activity, boosting BCAA catabolism, cell motility, and tumor development. BCAT1 KO-suppressed cell motility is rescued by BCAT1E61A expression or BCKA supplementation.\",\n      \"method\": \"Co-immunoprecipitation (BCAT1–RhoC interaction), RhoC GTPase activity assay, BCKA-RhoC direct binding assay, BCAT1 E61A mutant expression, BCAT1 knockout rescue experiments, in vitro motility assays, in vivo peritoneal metastasis model\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding assays (Co-IP, BCKA–RhoC), functional mutant rescue, multiple orthogonal readouts in single lab\",\n      \"pmids\": [\"37337119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of BCAT1 in IDH-wildtype GBM cells increases NAD+/NADH ratio but impairs oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis. Supplementing αKG in BCAT1-loss cells causes synthetic lethality (not seen with loss of BCAT2, BCKDHA, or GPT2). Synthetic lethality is prevented by supplementation with BCKA (downstream BCAT1 products), placing BCAT1 in the pathway supplying BCKA for mitochondrial metabolism and biosynthesis.\",\n      \"method\": \"Metabolic synthetic lethal screen, BCAT1 KO in patient-derived GBM cells, BCKA supplementation rescue, NAD+/NADH ratio measurement, mTORC1 activity assay, nucleotide quantification, in vivo xenograft model with gabapentin + αKG cotreatment\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — comprehensive metabolic profiling with genetic and pharmacological perturbations, in vitro and in vivo validation, metabolite rescue experiments\",\n      \"pmids\": [\"35499760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCAT1 enzymatic activity is required for osteoclast maturation: selective inhibition with gabapentin or expression of enzymatically dead BCAT1 (active-site mutant) abrogated RANKL-induced osteoclast differentiation. Valine was the most critical BCAA for osteoclast maturation, and BCAT1 activity sustains BCAA catabolism needed for this process.\",\n      \"method\": \"Gabapentin pharmacological inhibition, enzymatically dead BCAT1 mutant expression, RANKL-induced osteoclast differentiation assay, BCAA supplementation/depletion, in vivo LPS-induced calvarial bone loss model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic-dead mutant and pharmacological inhibitor with in vivo model, single lab\",\n      \"pmids\": [\"35760874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCAT1 binds the RNA-binding protein ZNF423 via AU-rich elements in the BCAT1 mRNA 3'-UTR (posttranscriptional regulation). BCAT1 protein then binds IRE1 on the ER to activate the IRE1–XBP-1–RIDD axis, leading to upregulation of BECN1 and Atg5 and autophagy activation in hypoxic pulmonary artery smooth muscle cells.\",\n      \"method\": \"RNA binding protein pulldown (ZNF423–BCAT1 mRNA), Co-IP (BCAT1–IRE1), BECN1/Atg5 protein expression assays, autophagy flux analysis in hypoxic PASMCs and rat model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and RNA pulldown for binding interactions, pathway activation measured with downstream markers, single lab\",\n      \"pmids\": [\"32938905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCKDK (branched chain ketoacid dehydrogenase kinase) phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability. STUB1 (CHIP) is the E3 ubiquitin ligase for BCAT1, ubiquitinating it for proteasomal degradation. BCKDK also phosphorylates STUB1 at S19, which disrupts the STUB1–BCAT1 interaction and inhibits BCAT1 ubiquitin-mediated degradation. This BCKDK–STUB1–BCAT1 cross-talk promotes GBM proliferation and temozolomide resistance.\",\n      \"method\": \"Phosphorylation site mapping (S5/S9/T312), BCKDK kinase assay, Co-IP (STUB1–BCAT1 interaction), ubiquitination assay (K48-linkage), STUB1 site mutants, in vivo and in vitro proliferation assays, temozolomide sensitivity assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-specific phosphorylation and ubiquitination with mutagenesis, Co-IP interaction studies, single lab\",\n      \"pmids\": [\"38621458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHIP (STUB1) acts as an E3 ubiquitin ligase for BCAT1, interacting via its coiled-coil domain with BCAT1 to promote K48-linkage ubiquitin degradation via the proteasome at Lys360. CHIP-mediated BCAT1 degradation induces metabolic reprogramming, reduces glutathione (GSH) synthesis, increases oxidative stress, and sensitizes glioma cells to temozolomide.\",\n      \"method\": \"Co-IP (CHIP–BCAT1), ubiquitination site mapping (Lys360), domain mapping (CHIP coiled-coil), proteasome inhibitor rescue, in vitro and in vivo tumor growth, GSH quantification\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct E3–substrate interaction with site mapping and functional consequences, single lab\",\n      \"pmids\": [\"39075053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SIRT5-mediated desuccinylation of BCAT1 at K39 inhibits BCAT1's interaction with the E3 ubiquitin ligase CHIP, preventing BCAT1 proteasomal degradation. BCAT1 stabilization by SIRT5 promotes glioma cell proliferation and ferroptosis resistance. BCAT1 overexpression rescues the proliferation inhibition and ferroptosis sensitivity caused by SIRT5 knockdown.\",\n      \"method\": \"SIRT5 knockdown, desuccinylation site mapping (K39), Co-IP (BCAT1–CHIP interaction), ubiquitin-proteasome degradation assay, BCAT1 overexpression rescue, ferroptosis assays, proteomic and metabolomic analyses\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PTM site-specific (K39 desuccinylation) with interaction and rescue experiments, single lab\",\n      \"pmids\": [\"40195331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DOT1L histone methyltransferase regulates BCAT1 expression through H3K79 methylation at the BCAT1 locus in breast cancer cells. BCAT1 was identified as a DOT1L target gene responsible for DOT1L-mediated sphere formation and cell migration.\",\n      \"method\": \"DOT1L knockdown and overexpression, H3K79 methylation ChIP at BCAT1 locus, BCAT1 expression analysis, sphere formation and migration assays\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP at BCAT1 locus linking H3K79me to transcription, functional knockdown assays, single lab\",\n      \"pmids\": [\"26783998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCAT1 depletion of αKG in lung cancer cells promotes expression of SOX2, a transcription factor regulating cancer cell stemness and metastasis. shRNA-mediated BCAT1 knockdown reduced αKG levels, increased SOX2 expression, reduced cell migration in vitro, and inhibited metastasis to distal organs in nude mice.\",\n      \"method\": \"shRNA knockdown of BCAT1, αKG quantification, SOX2 protein/mRNA measurement, in vitro migration assay, in vivo lung metastasis mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolite measurement and downstream transcription factor linked by loss-of-function, in vivo validation, single lab\",\n      \"pmids\": [\"34646394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy. Cisplatin upregulates BCAT1 expression; BCAT1 knockdown or leucine supplementation activates mTOR, inhibits autophagy, and increases cisplatin sensitivity. Chloroquine (autophagy inhibitor) phenocopies BCAT1 knockdown in vivo.\",\n      \"method\": \"BCAT1 knockdown, leucine/BCAA supplementation, mTOR signaling by Western blot, autophagy flux assays (LC3, p62), cisplatin sensitivity assays in vitro and in vivo, chloroquine inhibitor comparison\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary perturbations (KD, metabolite supplementation, pharmacological inhibitor) with in vivo confirmation, single lab\",\n      \"pmids\": [\"33568627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1-mediated BCAA catabolism generates leucine and other BCAAs that sustain SHOC2 (a leucine-rich repeat protein) expression, thereby maintaining the SHOC2-RAS-ERK signaling pathway and TNBC cell survival. Eupalinolide B (EB) directly binds and inhibits BCAT1 (confirmed by ABPP, pull-down, CETSA, MST), reducing BCAA synthesis, suppressing SHOC2-RAS-ERK signaling, and inducing apoptosis.\",\n      \"method\": \"Activity-based protein profiling (ABPP), pull-down Western blot, CETSA, microscale thermophoresis (MST) for EB–BCAT1 binding; HPLC metabolite quantification; SHOC2/RAS/ERK Western blot; in vivo mouse tumor model\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple direct binding assays for target identification, metabolite and pathway readouts, in vivo validation, single lab\",\n      \"pmids\": [\"39490614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NOTCH1 directly controls BCAT1 expression by binding to the BCAT1 promoter (ChIP validation). In a murine T-ALL model, Bcat1-deficient cells showed defects in developing leukemia. BCAT1 depletion in T-ALL cells redirected leucine metabolism toward production of 3-hydroxy butyrate (3-HB), an endogenous HDAC inhibitor, causing altered protein acetylation and sensitization to DNA-damaging agents.\",\n      \"method\": \"ChIP (NOTCH1 binding to BCAT1 promoter), Bcat1 genetic KO in murine T-ALL retroviral model, metabolomics (leucine to 3-HB pathway), protein acetylation analysis, etoposide sensitivity assay, patient-derived xenograft model\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct ChIP for transcription factor binding, genetic KO in disease model, metabolic pathway tracing with functional consequence, PDX validation\",\n      \"pmids\": [\"39234857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In CD4+ T cells, BCAT1 generates β-hydroxy β-methylbutyric acid (HMB) as a metabolite from cytosolic leucine catabolism through BCAT1 and HPD/HPDL enzymes. HMB upregulates HIF1α mRNA, activating the mTORC1–HIF1α pathway and increasing IL-17 production in Th17 cells. BCAT1 inhibition (Bi2 or L-β-homoleucine) or silencing attenuates IL-17 production; HMB supplementation rescues this effect. In vivo, BCAT1 blockade mitigated EAE severity.\",\n      \"method\": \"shRNA and pharmacological (Bi2, L-β-homoleucine) BCAT1 inhibition, HMB supplementation rescue, mTORC1–HIF1α pathway analysis (Western blot, RT-PCR), IL-17 ELISA, in vivo EAE mouse model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis with metabolite rescue and in vivo disease model, single lab\",\n      \"pmids\": [\"39085353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Overexpression of Bcat1/Eca39 in murine cells under serum deprivation leads to apoptotic cell death. The branched-chain keto acid α-ketoisocaproate (a product of BCAT1 leucine catabolism) can independently induce rapid apoptosis, suggesting BCAT1 promotes apoptosis via its metabolic products.\",\n      \"method\": \"Bcat1 overexpression in murine cells, cell viability assay under serum deprivation, α-ketoisocaproate treatment, apoptosis measurement\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct overexpression with apoptosis readout and metabolite treatment, single lab\",\n      \"pmids\": [\"10471790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Exogenous BDNF upregulates BCATc (BCAT1) mRNA and protein in astrocytes of the rat dorsal lateral geniculate nucleus following visual cortex lesion, as identified by mRNA fingerprinting and confirmed by RT-PCR and in situ hybridization. This upregulation is cell-type specific (astrocytes rather than neurons in this lesion context), suggesting that BDNF-mediated neuroprotection involves modulation of glutamate metabolism by astrocytes via BCATc.\",\n      \"method\": \"mRNA fingerprinting, quantitative RT-PCR, in situ hybridization, immunohistochemistry in rat visual cortex lesion model with intraocular BDNF delivery\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multi-method confirmation of BDNF-regulated BCATc expression in defined cell type in vivo, single lab\",\n      \"pmids\": [\"15233768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 promotes osteoclast maturation through BCAA catabolism; enzymatic activity is required (enzymatically dead mutant abrogates maturation). BCAT1 loss or inhibition reduces mTORC1/S6K1 phosphorylation in osteoclast precursors, and ROS increase. mTORC1 stimulation rescues proliferation and reduces ROS in BCAT1 knockdown muscle cells, placing BCAT1 upstream of mTORC1–S6K1 signaling.\",\n      \"method\": \"shRNA-resistant BCAT1 cDNA rescue, enzymatically dead BCAT1 mutant, mTORC1/S6K1 phosphorylation by Western blot, ROS measurement, BCAT1 KD and mTORC1 activator (MYH1485) co-treatment in C2C12 muscle cells\",\n      \"journal\": \"BMC musculoskeletal disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA-resistant rescue and mTOR activator epistasis, multiple readouts, single lab\",\n      \"pmids\": [\"35562710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAT1 promotes AML by restricting αKG levels, leading to impaired αKG-dependent histone demethylase (KDM) activity, elevated H3K9me3, suppressed ATM expression, and impaired DNA damage repair. High BCAT1 AML cells have increased sensitivity to PARP inhibitors.\",\n      \"method\": \"BCAT1 KO/OE AML cell lines, αKG quantification, histone methylation (H3K9me3) by Western blot, ATM expression analysis, DNA damage assays, PARP inhibitor (BMN673) sensitivity in vivo and in vitro\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolite-to-epigenome-to-DNA repair pathway with genetic and pharmacological tools, single lab\",\n      \"pmids\": [\"38340163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 in AML engages in bidirectional substrate reactions consuming BCAAs; BCAT1-driven leucine and αKG production activates mTOR (~2-fold higher p-S6K) in primary CLL cells with high BCAT1 expression. Disruption of BCAT1 in CLL-derived cell lines substantially reduces growth ex vivo.\",\n      \"method\": \"Steady-state metabolomics, heavy isotope metabolic tracing in primary CLL cells, p-S6K quantification by Western blot, BCAT1 disruption in cell lines\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — isotope tracing and metabolomics with mTOR pathway validation, single lab\",\n      \"pmids\": [\"39455853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In B cells, BCR/TLR9 costimulation highly induces BCAT1, which localizes to lysosomal membranes to support BCAA synthesis and mTORC1 activation. BCAT1 inhibition blunts BCR/TLR9-triggered (but not CD40L/IL-4-triggered) B cell proliferation, IL-10 expression, and lymphoma xenograft outgrowth.\",\n      \"method\": \"Transcriptomics, translatomics, and metabolomics of primary human B cells under distinct receptor stimuli; BCAT1 immunofluorescence localization to lysosomes; BCAT1 inhibition (pharmacological), BCR/TLR9 vs CD40L/IL-4 epistasis comparison; lymphoma xenograft model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiomic approach, direct subcellular localization, receptor-specific epistasis, in vivo xenograft validation\",\n      \"pmids\": [\"40924473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCAT1 activity in Müller cells is negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In diabetic conditions, elevated BCAT1 activity in Müller cells reduces intracellular αKG levels, increases H3K4me3 at promoters of inflammatory genes (IL-6, TNF-α), and boosts retinal inflammation. BCAT1 inhibitors reduce inflammatory gene expression and vascular leakage in diabetic retinas in vivo.\",\n      \"method\": \"ChIP (H3K4me3 at inflammatory gene promoters), kinase screening (Plk4→BCAT1 phospho-Thr333), BCAT1 inhibitors (BAY-069, ERG240) in diabetic mouse models, targeted metabolomics (αKG measurement in Müller cells), RNA-seq\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation site identified by kinase screening, ChIP for epigenetic mechanism, metabolomics, and in vivo pharmacology, single lab\",\n      \"pmids\": [\"40530920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAT1 is directly regulated by P2X1-mediated signaling: ATP–P2X1 signaling upregulates PBX3, which transactivates BCAT1. P2X1 phosphorylation at S387 and T389 is required for its leukemia-promoting effects. P2X1 deletion impairs leukemia-initiating cell (LIC) self-renewal in AML, an effect mediated through the PBX3–BCAT1 pathway.\",\n      \"method\": \"P2X1 genetic deletion, P2X1 phospho-site mutants (S387A/T389A), ChIP/transactivation assay (PBX3 on BCAT1), AML mouse transplant model, human AML cell line knockdown\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis (P2X1→PBX3→BCAT1) with site-specific phospho mutants and in vivo transplant model, single lab\",\n      \"pmids\": [\"36418376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCAA/BCAT1 signaling enhances phosphorylation of CREB in TKI-resistant CML cells, which is required for maintenance of TKI-resistant leukemia. BCAT1 knockdown or BCAA deprivation abolishes CREB phosphorylation and leukemogenesis in a BCR-ABL T315I murine CML model.\",\n      \"method\": \"BCAT1 knockdown, BCAA stimulation in vitro, CREB phosphorylation by Western blot, BCR-ABLT315I murine transplant CML model, human TKI-resistant cell line proliferation assays\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis (BCAA→BCAT1→pCREB) with in vivo model, single lab\",\n      \"pmids\": [\"39412615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Transcription factor EB (TFEB) directly regulates BCAT1 transcription to reprogram BCAA catabolism in pancreatic cancer cells. TFEB knockdown blocks BCAA catabolism by reducing BCAT1 expression, inhibiting proliferation and metastasis; combined BCAA deprivation and TFEB inhibition (eltrombopag) synergistically inhibits pancreatic cancer cell proliferation.\",\n      \"method\": \"TFEB knockdown (siRNA), BCAT1 mRNA/protein measurement, BCAA metabolomics, BCAA deprivation combined with eltrombopag treatment, proliferation and metastasis assays\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — transcriptional regulation epistasis with metabolomics, single lab, no direct ChIP reported in abstract\",\n      \"pmids\": [\"38938061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HuR RNA-binding protein directly interacts with BCAT1 mRNA, increasing its stability and translation, thereby upregulating BCAT1 protein and activating ERK5 signaling in castration-resistant prostate cancer. HuR KO or the HuR inhibitor KH-3 (which disrupts HuR–BCAT1 mRNA interaction) reduces BCAT1 expression and suppresses CRPC progression.\",\n      \"method\": \"HuR knockout (Cas9), mRNA half-life assay, RIP (HuR–BCAT1 mRNA), HuR inhibitor KH-3, ERK5 signaling by Western blot, xenograft tumor model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RIP for mRNA binding, mRNA stability assay, signaling pathway validation, in vivo confirmation, single lab\",\n      \"pmids\": [\"38369471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-124-3p directly targets the BCAT1 mRNA 3'-UTR, resulting in BCAT1 upregulation when miR-124-3p is suppressed. DNMT1-mediated promoter hypermethylation silences miR-124-3p expression, establishing a DNMT1→miR-124-3p→BCAT1 axis that promotes ESCC proliferation and migration.\",\n      \"method\": \"miR-124-3p target validation (3'-UTR reporter/sequence analysis), DNMT1 knockdown and inhibition, miR-124-3p and BCAT1 expression in ESCC cell lines and tissues\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — epigenetic regulation axis with miRNA targeting, single lab, abstract does not explicitly state luciferase reporter confirmation of miR-124-3p/BCAT1 3'-UTR interaction\",\n      \"pmids\": [\"31226958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCAT1 activates the PI3K/AKT/mTOR pathway in gastric cancer cells, and pharmacological blockade with LY294002 reverses tumor growth induced by BCAT1 overexpression. BCAT1 promotes angiogenesis, invasion, and proliferation through this pathway.\",\n      \"method\": \"BCAT1 lentiviral overexpression/silencing, PI3K/AKT/mTOR pathway Western blot, LY294002 PI3K inhibitor rescue, xenograft model, angiogenesis assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — pharmacological epistasis with inhibitor rescue, in vivo xenograft, single lab\",\n      \"pmids\": [\"34164393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCATc (BCAT1) knockdown in TNBC cells significantly reduced insulin- and IGF-1-mediated proliferation, migration, and invasion. BCATc overexpression regulates proliferation through the PI3K/Akt axis while simultaneously attenuating the Ras/ERK pathway, ultimately increasing FOXO3a and Nrf2.\",\n      \"method\": \"BCATc siRNA knockdown and overexpression, IGF-1/insulin stimulation, PI3K/Akt and Ras/ERK pathway Western blot, FOXO3a and Nrf2 protein levels, proliferation and invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — gain- and loss-of-function with dual-pathway analysis, single lab\",\n      \"pmids\": [\"32523652\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCAT1 (BCATc) is a cytosolic branched-chain amino acid transaminase that catalyzes the first step of BCAA catabolism (transamination to αKG), thereby consuming αKG, generating glutamate and branched-chain α-keto acids (BCKAs), and regulating intracellular αKG homeostasis; through αKG depletion, BCAT1 limits TET-mediated DNA demethylation and αKG-dependent histone demethylation, causing epigenetic hypermethylation that mimics IDH mutation effects in cancer. BCAT1-derived BCKAs and leucine activate mTORC1 signaling to drive cell proliferation, mitochondrial biogenesis, and immune cell function, while BCAT1 also directly interacts with RhoC (promoting its GTPase activity via BCKA binding) and localizes to lysosomal membranes and mitotic structures where it exerts non-metabolic roles: a conserved CXXC redox motif controls cysteine sulfenylation, promotes Aurora kinase B localization to centromeres, and maintains mitotic fidelity. BCAT1 expression is transcriptionally controlled by c-Myc (direct promoter binding), NOTCH1 (direct promoter binding), DOT1L-mediated H3K79 methylation, STAT3 activation, and TFEB, and its protein stability is regulated by BCKDK-mediated phosphorylation (which increases activity and blocks STUB1/CHIP-mediated K48-ubiquitination and proteasomal degradation) and SIRT5-mediated desuccinylation at K39.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCAT1 (BCATc) is a cytosolic branched-chain amino acid transaminase that initiates BCAA catabolism by transferring amino groups from BCAAs to \\u03b1-ketoglutarate (\\u03b1KG), thereby consuming \\u03b1KG, generating glutamate and branched-chain \\u03b1-keto acids (BCKAs), and serving as a central regulator of intracellular \\u03b1KG homeostasis across cancer and immune contexts [#0, #1]. By depleting \\u03b1KG, BCAT1 restrains \\u03b1KG-dependent dioxygenases\\u2014reducing TET activity to cause DNA hypermethylation that mimics IDH mutation [#1], impairing KDM histone demethylases to elevate H3K9me3 and suppress ATM-dependent DNA repair [#25], and reciprocally driving promoter H3K4me3 at inflammatory genes [#28]\\u2014and stabilizing HIF1\\u03b1 by limiting EGLN1 activity [#1]. Its catabolic products feed anabolic signaling: BCKA and leucine sustain mitochondrial metabolism, nucleotide biosynthesis, and mTORC1 activity, with \\u03b1KG supplementation producing synthetic lethality in BCAT1-null glioblastoma [#10, #3]. BCAT1 also exerts catalysis-independent functions through a conserved CXXC redox motif that metabolizes H2O2, buffers ROS, and\\u2014during mitosis\\u2014promotes Aurora kinase B localization to centromeres to maintain chromosome segregation fidelity [#7, #8]. Beyond transamination, BCAT1 directly binds RhoC to elevate its GTPase activity, an interaction reinforced by BCKA binding to RhoC, thereby promoting cell motility [#9]. BCAT1 expression is driven transcriptionally by c-Myc and NOTCH1 promoter binding and by DOT1L-mediated H3K79 methylation [#4, #20, #16], while its protein stability is controlled by BCKDK phosphorylation and SIRT5 desuccinylation that antagonize STUB1/CHIP-mediated K48 ubiquitination and proteasomal degradation [#13, #14, #15]. Through these axes BCAT1 supports proliferation, stemness, and therapy resistance in multiple cancers, lymphocyte and osteoclast function, and is induced in neurons and astrocytes consistent with a role in glutamate metabolism [#6, #23, #20, #27].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that BCAT1 metabolic products themselves can drive cell fate, showing that a keto-acid product of leucine catabolism induces apoptosis.\",\n      \"evidence\": \"Bcat1/Eca39 overexpression in murine cells under serum deprivation with \\u03b1-ketoisocaproate treatment\",\n      \"pmids\": [\"10471790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking keto-acid to apoptotic machinery not defined\", \"Single overexpression system without endogenous validation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the in vivo expression pattern of BCATc in neural tissue, linking it to glutamate metabolism in distinct neuronal and astrocytic compartments.\",\n      \"evidence\": \"Immunohistochemistry across rat brain regions; mRNA fingerprinting and in situ hybridization in a BDNF-treated visual cortex lesion model\",\n      \"pmids\": [\"15329886\", \"15233768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of neuronal vs astrocytic localization not tested\", \"No direct measurement of neurotransmitter pools\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified BCAT1 as a driver of BCAA catabolism and glutamate excretion in glioma and showed its expression is governed by \\u03b1KG availability and antagonized by mutant IDH1, linking it to the IDH oncometabolite axis; concurrently established c-Myc as a direct transcriptional activator.\",\n      \"evidence\": \"shRNA knockdown and xenografts in glioma; ectopic mutant IDH1 in astrocytes; ChIP and luciferase reporter for c-Myc on the BCAT1 promoter\",\n      \"pmids\": [\"23793099\", \"23758864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct epigenetic consequences of \\u03b1KG depletion not yet measured here\", \"Mechanism by which IDH1 mutation suppresses BCAT1 not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected BCAT1 to immune signaling by showing TCR-induced BCATc lowers intracellular leucine to restrain mTORC1 and glycolysis in CD4+ T cells, with NFAT placed upstream.\",\n      \"evidence\": \"BCATc knockout mouse, leucine transamination assays, mTORC1 phospho-readouts, cyclosporin A inhibition\",\n      \"pmids\": [\"24847056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether leucine depletion is the sole mTORC1-limiting mechanism unclear\", \"Context-dependence relative to anabolic roles in cancer not reconciled\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established the core mechanistic principle that BCAT1 controls intracellular \\u03b1KG to govern HIF1\\u03b1 stability and TET-dependent DNA methylation, mimicking IDH mutation, and links BCAA catabolism to mitochondrial biogenesis via mTOR.\",\n      \"evidence\": \"BCAT1 gain/loss in leukemia cells with metabolomics, HIF1\\u03b1/TET assays, DNA methylation profiling; breast cancer mTOR/AMPK/SIRT1 analysis\",\n      \"pmids\": [\"29144447\", \"28235484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of \\u03b1KG-mediated epigenetic effects across tissues not yet shown\", \"mTOR activation mechanism (metabolite vs other) not fully defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified epigenetic transcriptional control of BCAT1 via DOT1L-mediated H3K79 methylation in breast cancer.\",\n      \"evidence\": \"DOT1L knockdown/overexpression, H3K79me ChIP at BCAT1 locus, sphere/migration assays\",\n      \"pmids\": [\"26783998\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect DOT1L effect on BCAT1 not separated\", \"Single lineage context\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded BCAT1 regulation to additional transcriptional and post-transcriptional inputs and to stromal supply roles, showing TGF-\\u03b2/SMAD5 control in fibroblasts and an RNA-binding/ER-stress axis driving autophagy.\",\n      \"evidence\": \"TGF-\\u03b2/SMAD5 perturbation and isotope tracing in CAFs; ZNF423\\u2013BCAT1 mRNA pulldown and BCAT1\\u2013IRE1 Co-IP in hypoxic PASMCs\",\n      \"pmids\": [\"32694827\", \"32938905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SMAD5 binding to BCAT1 not shown\", \"Non-metabolic IRE1 interaction lacks structural detail\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Broadened BCAT1's downstream signaling outputs and physiological roles, linking it to mTOR-driven autophagy and chemoresistance, PI3K/AKT and Ras/ERK signaling, SOX2-dependent stemness, and enzyme-dependent osteoclast maturation.\",\n      \"evidence\": \"Knockdown/overexpression with pathway Western blots and inhibitors (LY294002, chloroquine), \\u03b1KG/SOX2 quantification, catalytic-dead BCAT1 mutants and gabapentin in osteoclast/muscle systems, in vivo models\",\n      \"pmids\": [\"33568627\", \"34164393\", \"32523652\", \"34646394\", \"35760874\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether mTOR/PI3K effects are direct or metabolite-driven not always resolved\", \"Tissue-specific reconciliation of pro- vs anti-mTOR effects pending\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed catalysis-independent functions of BCAT1, defining the CXXC redox motif as a peroxide-metabolizing antioxidant module that controls mitotic Aurora B localization and chromosome segregation, and demonstrating \\u03b1KG synthetic lethality and \\u03b1KG-dependent epigenetic/DNA-repair control.\",\n      \"evidence\": \"CXXC separation-of-function rescue with live imaging and sulfenylation assays; in vitro H2O2 metabolism with purified protein; metabolic synthetic-lethal screens with BCKA/\\u03b1KG rescue; H3K9me3/ATM/PARP-inhibitor analyses\",\n      \"pmids\": [\"36260995\", \"35453368\", \"35499760\", \"38340163\", \"35562710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of BCAT1\\u2013Aurora B coupling unknown\", \"How redox and metabolic functions are partitioned in vivo unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated a direct non-metabolic protein interaction by which BCAT1 binds RhoC to elevate its GTPase activity, with BCKA acting as a direct RhoC ligand, and identified a gain-of-function mutation enhancing this axis.\",\n      \"evidence\": \"Co-IP, RhoC GTPase and BCKA-RhoC binding assays, BCAT1 E61A mutant and KO rescue, in vivo metastasis model\",\n      \"pmids\": [\"37337119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural interface of BCAT1\\u2013RhoC binding not defined\", \"Reciprocal validation of interaction in additional systems limited\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped the post-translational and transcriptional control network stabilizing BCAT1\\u2014BCKDK phosphorylation and STUB1/CHIP ubiquitination at defined sites\\u2014and added NOTCH1, TFEB, PBX3, HuR, and CREB-linked inputs while detailing metabolite-driven immune and leukemic phenotypes.\",\n      \"evidence\": \"Phospho/ubiquitin site mapping and Co-IP for BCKDK\\u2013STUB1\\u2013BCAT1; ChIP for NOTCH1; TFEB/PBX3/HuR perturbations with RIP and metabolomics; metabolite tracing to 3-HB and HMB with EAE, AML, CML, and B-cell/lymphoma models\",\n      \"pmids\": [\"38621458\", \"39075053\", \"39234857\", \"38938061\", \"36418376\", \"38369471\", \"39085353\", \"39455853\", \"39412615\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy and cross-talk among multiple regulators not integrated\", \"Several transcriptional links lack direct promoter-binding evidence\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked subcellular localization and an additional PTM to BCAT1 function, showing lysosomal-membrane localization supporting BCAA synthesis and mTORC1 in B cells, SIRT5 desuccinylation at K39 stabilizing BCAT1 against CHIP degradation, and Plk4 phosphorylation negatively regulating its \\u03b1KG-dependent epigenetic activity.\",\n      \"evidence\": \"Multiomics and immunofluorescence in primary B cells; SIRT5 knockdown with K39 desuccinylation mapping and CHIP Co-IP; Plk4 phospho-Thr333 mapping with ChIP and \\u03b1KG metabolomics in M\\u00fcller cells\",\n      \"pmids\": [\"40924473\", \"40195331\", \"40530920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of lysosomal recruitment unknown\", \"Interplay between SIRT5, BCKDK, and CHIP on the same protein not jointly tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BCAT1's metabolic, redox/CXXC, and direct protein-interaction (RhoC, Aurora B, IRE1) functions are coordinated and partitioned within a cell, and what determines its divergent mTORC1 outcomes across cell types, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating catalytic and non-catalytic domains\", \"Spatial coordination of cytosolic, lysosomal, and mitotic pools undefined\", \"Context determinants of pro- vs anti-mTORC1 activity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 3, 10, 11]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 25, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 9, 34]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 21, 27]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 14, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RhoC\", \"STUB1\", \"BCKDK\", \"SIRT5\", \"IRE1\", \"ZNF423\", \"HuR\", \"Plk4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"loss","faith_supported":7,"faith_total":7,"faith_pct":100.0}}